Intensive glucose lowering treatment has no significant benefit on all-cause mortality and cardiovascular-related deaths in patients with type 2 diabetes and should be considered with “caution” in these patients, experts say.
A meta-analysis of 13 randomised trials involving 34,533 patients with type 2 diabetes, found intensive oral or insulin glucose lowering treatment showed no significant affect on all- cause mortality or cardiovascular deaths, when compared with standard treatment.
Intensive therapy did reduce the risk of non-fatal myocardial infarction (MI) and microalbuminuria, but was also associated with more than two-fold increase in a risk of severe hypoglycaemia.
“The favourable results on non-fatal MI and microalbuminuria did not remain significant when the analysis was restricted to...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.